Lunsotogene Parvec Becomes First FDA-Approved Gene Therapy for OTOF-Related Hearing Loss

Why It Matters

The approval introduces a disease‑modifying option for a genetic deafness that previously required invasive implants, potentially reshaping clinical practice and payer economics in audiology.

Key Takeaways

• First FDA‑approved gene therapy for OTOF‑related hearing loss
• 80% of trial participants achieved hearing ≤70 dB HL at 24 weeks
• Regeneron will provide Otarmeni at no cost to eligible U.S. patients
• Approved under National Priority Voucher, marking a new regulatory pathway

Pulse Analysis

The approval of lunsotogene parvec‑cwha, branded Otarmeni, marks a watershed moment in the nascent field of auditory gene therapy. OTOF‑related deafness, caused by biallelic mutations in the otoferlin gene, accounts for a notable fraction of congenital severe-to-profound sensorineural hearing loss, yet no disease‑modifying treatments have existed. By delivering a functional copy of OTOF directly to inner‑ear hair cells via an adeno‑associated virus vector, Regeneron has turned a genetic defect into a treatable condition. This breakthrough expands the therapeutic horizon beyond the more common retinal and muscular targets that have dominated recent approvals.

The pivotal CHORD phase 1/2 trial delivered compelling efficacy signals: 80 % of evaluable participants reached an average hearing threshold of 70 dB HL or better, a level that typically restores functional acoustic perception and eliminates the need for cochlear implantation. Moreover, 42 % achieved normal‑range hearing, including the ability to detect whispers, within the same 24‑week window. The single intracochlear infusion, administered once, simplifies the treatment paradigm and reduces procedural risk compared with repeated dosing strategies. Early safety data showed no serious adverse events, reinforcing confidence in AAV‑mediated inner‑ear delivery.

Regeneron’s decision to supply Otarmeni free of charge to eligible U.S. patients underscores a strategic shift toward value‑based access in high‑cost biologics. The therapy’s approval under the FDA Commissioner’s National Priority Voucher program also signals a new regulatory pathway that can accelerate market entry for transformative medicines. Analysts anticipate that the commercial launch will stimulate investment in other genetic hearing loss programs, while insurers will grapple with reimbursement models for a therapy that eliminates downstream costs of implants and rehabilitation. Ultimately, Otarmeni could set a precedent for how gene therapies are priced, delivered, and integrated into standard care.